Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
UNITED STATES, AUG 7 – Orforglipron led to 12% average weight loss in an 18-month trial of over 3,000 adults with obesity, with 60% losing at least 10%, company data show.
- On August 7, 2025, Eli Lilly reported successful primary outcomes from its global Phase 3 ATTAIN-1 study evaluating orforglipron, an oral medication for obesity.
- The 72-week trial involved 3,127 adults with obesity or overweight and weight-related conditions but no diabetes, aiming to surpass placebo in body weight reduction.
- Participants on the highest 36 mg dose lost an average of 12.4% body weight , and 59.6% lost at least 10%, with side effects similar to injectable GLP-1 drugs.
- Eli Lilly aims to file for regulatory approval of orforglipron by the end of the year and is investing over $600 million in production capacity to support anticipated demand for its worldwide introduction in response to critical health challenges.
- The results position orforglipron as a convenient once-daily oral alternative for obesity treatment, with detailed data expected at a September conference and possible market entry next year.
73 Articles
73 Articles
A new group of active ingredients helps with diabetes and obesity. Up to now, such drugs have mainly been used as a syringe. Now, a manufacturer provides data on a decrease pill.
No longer inject, but swallow: pharmaceutical manufacturers work on tablets against obesity. Preliminary study data show: they work. However, apparently a little less effective than weight loss injections.
So far, the medications in the fight against obesity were only available as a syringe. Eli Lilly, a pharmaceutical company, has now published the first clinical data on the weight loss pill. Will the tablet revolutionize obesity treatment?
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium